SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

SAN

76.31

-1.27%↓

ARGX

765

+0.79%↑

SHL.DE

34.95

+0.26%↑

PHIA

22.42

-1.67%↓

FRE

37.73

+0.77%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Avatud

28.68 -7.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.12

Max

30.6

Põhinäitajad
By Trading Economics
Sissetulek	-13M -19M
Müük	-24M 3M
Kasumimarginaal	-618.236
Töötajad	100
EBITDA	-14M -13M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+78.92% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. juuni 2026

Turustatistika
By TradingEconomics
Turukapital	233M 1.6B
Eelmine avamishind	35.86
Eelmine sulgemishind	28.68

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. juuni 2026, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. juuni 2026, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. juuni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. juuni 2026, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. juuni 2026, 20:51 UTC

Tulu

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. juuni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. juuni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. juuni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. juuni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. juuni 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. juuni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. juuni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. juuni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. juuni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. juuni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. juuni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. juuni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

78.92% tõus

12 kuu keskmine prognoos

Keskmine 55 EUR 78.92%

Kõrge 60 EUR

Madal 45 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.